Compare Amgen, Inc. (AMGN) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Duke Energy Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Duke Energy Corp trades at $125.93 (market cap $97.82B). The key difference: Amgen, Inc. is far larger — about 2× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.39%). Which is the better fit depends on your goals.
| AMGN | DUK | |
|---|---|---|
Market Cap | $196.12B | $97.82B |
Sector | Health | Utilities |
52-Week High | $388.16 | $133.46 |
52-Week Low | $271.18 | $113.99 |
Enterprise Value | $241.41B | $187.87B |
Dividend Yield | 2.77% | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Duke Energy (DUK) trades at $125.48, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue growth to $32.24B in 2025 and a net income margin of 15.49%, supported by a dividend yield from its recent $1.07 payout. Analyst consensus is mixed with 40.6% buy ratings and a $137.67 price target, indicating potential upside. Technical resistance sits at $127, with support at $124.
DUK offers defensive appeal with consistent profitability and dividend reliability, but faces headwinds from high debt levels (46.17% debt-to-asset ratio) and capital-intensive infrastructure demands. The stock's neutral RSI and bearish moving averages suggest near-term consolidation, while long-term growth hinges on execution in a regulated utility environment amid rising data center energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
